Literature DB >> 16524427

NF-kappaB activation in melanoma.

Yukiko Ueda1, Ann Richmond.   

Abstract

Metastatic melanoma is an aggressive skin cancer that is notoriously resistant to current cancer therapies. In human melanoma, nuclear factor-kappa B (NF-kappaB) is upregulated, leading to the deregulation of gene transcription. In this review, we discuss (i) the relationship between gene alteration in melanoma and upregulation of NF-kappaB, (ii) mechanisms by which activated NF-kappaB switch from pro-apoptotic to anti-apoptotic functions in melanoma and (iii) autocrine mechanisms that promote constitutive activation of NF-kappaB in metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16524427      PMCID: PMC2668252          DOI: 10.1111/j.1600-0749.2006.00304.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  180 in total

1.  p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression.

Authors:  V N Ivanov; Z Ronai
Journal:  Oncogene       Date:  2000-06-15       Impact factor: 9.867

2.  Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages.

Authors:  B Vanhaesebroeck; G E Jones; W E Allen; D Zicha; R Hooshmand-Rad; C Sawyer; C Wells; M D Waterfield; A J Ridley
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

Review 3.  Genes involved in melanoma: an overview of INK4a and other loci.

Authors:  M Castellano; G Parmiani
Journal:  Melanoma Res       Date:  1999-10       Impact factor: 3.599

4.  Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice.

Authors:  S Huang; A DeGuzman; C D Bucana; I J Fidler
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.

Authors:  O Straume; L Sviland; L A Akslen
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

6.  Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling.

Authors:  A Takaori-Kondo; T Hori; K Fukunaga; R Morita; S Kawamata; T Uchiyama
Journal:  Biochem Biophys Res Commun       Date:  2000-06-16       Impact factor: 3.575

7.  Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis.

Authors:  I K Campbell; S Gerondakis; K O'Donnell; I P Wicks
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Shc products are substrates of erbB-2 kinase.

Authors:  O Segatto; G Pelicci; S Giuli; G Digiesi; P P Di Fiore; J McGlade; T Pawson; P G Pelicci
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

9.  Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop.

Authors:  J Hiscott; J Marois; J Garoufalis; M D'Addario; A Roulston; I Kwan; N Pepin; J Lacoste; H Nguyen; G Bensi
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

10.  Common structural constituents confer I kappa B activity to NF-kappa B p105 and I kappa B/MAD-3.

Authors:  E N Hatada; M Naumann; C Scheidereit
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  70 in total

Review 1.  Influence of arsenate and arsenite on signal transduction pathways: an update.

Authors:  Ingrid L Druwe; Richard R Vaillancourt
Journal:  Arch Toxicol       Date:  2010-05-26       Impact factor: 5.153

2.  Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation.

Authors:  Jian Huang; Keqiang Chen; Jiaqiang Huang; Wanghua Gong; Nancy M Dunlop; O M Zack Howard; Xiuwu Bian; Yuqi Gao; Ji Ming Wang
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

3.  Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome.

Authors:  Mithalesh Kumar Singh; Lata Singh; Kunzang Chosdol; Neelam Pushker; Neeru Saini; Rachna Meel; Sameer Bakhshi; Seema Sen; Seema Kashyap
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-14       Impact factor: 4.553

4.  MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.

Authors:  Mengyu Xie; Hong Zheng; Ranjna Madan-Lala; Wenjie Dai; Nicholas T Gimbrone; Zhihua Chen; Fumi Kinose; Sarah A Blackstone; Keiran S M Smalley; W Douglas Cress; Eric B Haura; Uwe Rix; Amer A Beg
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

5.  Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

Authors:  Mohammad A Shahshahan; Maureen N Beckley; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2011-08-23       Impact factor: 6.166

6.  The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization.

Authors:  Jasna Lojk; Sonja Prpar Mihevc; Vladimir Boštjan Bregar; Mojca Pavlin; Boris Rogelj
Journal:  Neurotox Res       Date:  2017-04-25       Impact factor: 3.911

7.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.

Authors:  Radoslav Janostiak; Navin Rauniyar; TuKiet T Lam; Jianhong Ou; Lihua J Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.

Authors:  Jinming Yang; Snjezana Zaja-Milatovic; Yee-Mon Thu; Francis Lee; Richard Smykla; Ann Richmond
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

10.  A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.

Authors:  J S Blackburn; I Liu; C I Coon; C E Brinckerhoff
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.